Review
Open access
Sep 2026
Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer
BRCA1/2 mutation status is a key biomarker in the management of ovarian cancer, supporting personalized treatment strategies and improving patient outcomes, and emerging mechanisms of resistance to PARP inhibitors remain a significant therapeutic challenge.
Weronika Pawul, Paulina Opoka, Agata Dusza et al.
· Frontiers in Oncology · 0 citations